Reaction

Opportunistic Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,830 reports · 58 co-occurring drugs

As of the last recalculation, Opportunistic Infection appears in 1,830 FAERS reports alongside 58 co-occurring drug terms. The strongest observed disproportionality signal is NATALIZUMAB (PRR 42.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Natalizumab	494	42.0	42.1
Polatuzumab Vedotin	20	23.6	23.6
Ganciclovir Sodium	18	19.5	19.6
Bendamustine Hydrochloride	20	19.2	19.2
Sirolimus	20	17.1	17.1
Obinutuzumab	24	16.8	16.8
Ganciclovir	15	16.8	16.8
Alemtuzumab	28	16.7	16.7
Remdesivir	18	15.5	15.5
Abacavir Sulfate	13	15.3	15.3
Lopinavir And Ritonavir	18	15.2	15.3
Lamivudine Oral	33	15.1	15.1
Lamivudine	38	14.3	14.3
Anakinra	19	13.2	13.2
Tacrolimus Ointment 0.1%	126	12.3	12.3
Tacrolimus Extended-Release Capsules	126	12.3	12.3
Zidovudine	14	12.0	12.0
Mycophenolate Mofetil	128	11.4	11.5
Mycophenolate Mofetil Hydrochloride	128	11.4	11.4
Nevirapine	9	11.4	11.4
Brentuximab Vedotin	10	11.2	11.2
Tacrolimus	141	11.0	11.0
Prednisolone	145	9.8	9.8
Prednisolone Oral	145	9.8	9.8
Prednisolone Oral Solution	145	9.8	9.8
Tofacitinib Citrate	11	9.6	9.6
Diphenhydramine Hcl	9	9.2	9.2
Ritonavir 100 Mg	12	9.2	9.2
Cyclosporine	81	8.6	8.6
Temozolomide	15	8.2	8.2
Fludarabine Phosphate	27	7.9	7.9
Rifampicin	7	7.9	7.9
Cyclophosphamide Injection, Solution	113	7.7	7.7
Cyclophosphamide	113	7.7	7.7
Cyclophosphamide For Injection	113	7.7	7.7
Rituximab	132	7.6	7.6
Melphalan	15	7.6	7.6
Pyrazinamide	6	7.3	7.3
Infliximab	131	7.3	7.3
Efavirenz	7	7.2	7.2
Baricitinib	6	7.1	7.1
Ritonavir	18	7.1	7.1
Isoniazid	10	7.1	7.1
Raltegravir	10	6.9	6.9
Piperacillin Sodium,Tazobactam Sodium	16	6.9	6.9
Melphalan Hydrochloride	15	6.9	6.9
Cladribine	5	5.9	5.9
Atezolizumab	20	5.9	5.9
Bendamustine Hcl	8	5.9	5.9
Cytarabine	30	5.8	5.8
Doxorubicin Hydrochloride	15	5.3	5.3
Doxorubicin	39	5.1	5.1
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	4	4.5	4.5
Gemcitabine	15	4.4	4.4
Venetoclax	23	4.3	4.3
Fam-Trastuzumab Deruxtecan-Nxki	3	3.4	3.4
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	5	3.1	3.1
Durvalumab	5	2.8	2.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.